Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of the stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $77.42, for a total transaction of $232,260.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
James J. Vaughn also recently made the following trade(s):
- On Tuesday, January 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $67.06, for a total transaction of $201,180.00.
- On Thursday, December 6th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $75.30, for a total transaction of $225,900.00.
GHDX stock traded up $1.73 during trading on Monday, hitting $80.42. 258,832 shares of the company’s stock traded hands, compared to its average volume of 332,858. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 8,042.00 and a beta of 0.88. Genomic Health, Inc. has a 1 year low of $30.04 and a 1 year high of $92.18.
A number of hedge funds have recently modified their holdings of GHDX. Royce & Associates LP increased its holdings in Genomic Health by 22.8% during the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock valued at $95,000 after buying an additional 273 shares during the period. Advisor Group Inc. boosted its stake in Genomic Health by 34.9% in the fourth quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 516 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Genomic Health in the third quarter valued at approximately $171,000. Quantamental Technologies LLC acquired a new stake in Genomic Health in the fourth quarter valued at approximately $180,000. Finally, Trexquant Investment LP acquired a new stake in Genomic Health in the third quarter valued at approximately $202,000. 90.09% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4144439/genomic-health-inc-ghdx-insider-james-j-vaughn-sells-3000-shares.html.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Recommended Story: What is the S&P 500 Index?
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.